UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 1, 2019
PhaseBio Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)
|
Delaware
|
001-38697
|
03-0375697
|
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
|
1 Great Valley Parkway, Suite 30
Malvern, Pennsylvania
|
|
19355
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
(610) 981-6500
(Registrant’s Telephone Number, Including Area Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communicati
ons pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
Common Stock
|
PHAS
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.
405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company
☒
If an
emerging
growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Item 8.01 Other Events.
On July 1, 2019, PhaseBio Pharmaceuticals, Inc. issued a press release announcing that the company has been added to the Russell 2000
®
and 3000
®
Indexes, effective after U.S. market close on Friday, June 28, 2019. The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01
Financial Statements and Exhibits.
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
PhaseBio Pharmaceuticals, Inc.
|
|
|
|
|
|
|
Dated: July 1, 2019
|
|
|
|
By:
|
|
/s/ John Sharp
|
|
|
|
|
|
|
|
John Sharp
|
|
|
|
|
|
|
|
Chief Financial Officer
|
|
|
|
|
|
Exhibit 99.1
|
PhaseBio
Added to Russell 2000
®
and 3000
®
Indexes
Malvern, PA, and San Diego, CA, July 1, 2019
—
PhaseBio Pharmaceuticals, Inc.
(Nasdaq: PHAS),
a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for orphan diseases, today announced that the company has been added to the Russell 2000
®
and 3000
®
Indexes, effective after U.S. market close on Friday, June 28, 2019, following Russell’s annual reconstitution of its U.S. and global equity indexes.
The Russell 2000
®
Index measures the performance of the small-cap segment of the U.S. equity market. The Russell 2000
®
Index is a subset of the Russell 3000
®
Index and represents approximately 10 percent of the total market capitalization of that index.
“We are pleased to be added to the Russell 2000 and 3000 Indexes,” said John Sharp, Chief Financial Officer of PhaseBio. “This reflects our positive progress in the advancement of our clinical programs, including PB2452 for the reversal of the antiplatelet activity of ticagrelor and PB1046 for the treatment of pulmonary arterial hypertension, as well as the shareholder value we’ve created
.”
Membership in Russell U.S. indexes is determined primarily by objective, market-capitalization rankings and style attributes. Approximately $8.6 trillion in assets are benchmarked against Russell’s U.S. indexes. Russell indexes are part of FTSE Russell, a leading global index provider.
For more information about the Russell Indexes, visit
www.ftserussell.com
.
About PhaseBio
PhaseBio Pharmaceuticals, Inc.
is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary disorders. The company’s lead development candidate is PB2452, a novel reversal agent for the antiplatelet therapy ticagrelor. PhaseBio is also leveraging its proprietary elastin-like polypeptide (“ELP”) technology platform to develop therapies with the potential for less-frequent dosing and improved pharmacokinetics. PhaseBio’s second product candidate PB1046, which is based on ELP, is a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension.
PhaseBio is located in Malvern, PA and San Diego, CA. For more information, please visit
www.phasebio.com
.
###
Investor Contact:
John Sharp
PhaseBio Pharmaceuticals, Inc.
Chief Financial Officer
(610) 981-6506
john.sharp@phasebio.com
Media Contact:
Gina Cestari
6 Degrees
(917) 797-7904
gcestari@6degreespr.com